Spectrum to re-submit Fusilev for colorectal cancer in the US
This article was originally published in Scrip
Spectrum Pharmaceuticals has met the US FDA to discuss the complete response letter it received for the NDA for its injectable chemotherapy drug Fusilev (levoleucovorin) for advanced metastatic colorectal cancer. The company said it would be able to respond to the agency's requests by the end of the third quarter of this year.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.